User Behavior-Based Implicit Authentication

In this work, we proposed dynamic retraining (RU), wind vane module (WVM), BubbleMap (BMap), and reinforcement authentication (RA) to improve the efficacy of implicit authentication (IA). Motivated by the great potential of implicit and seamless user authentication, we have built an implicit authentication system with adaptive sampling that automatically selects dynamic sets of activities for user behavior extraction. Various activities, such as user location, application usage, user motion, and battery usage have been popular choices to generate behaviors, the soft biometrics, for implicit authentication. Unlike password-based or hard biometric-based authentication, implicit authentication does not require explicit user action or expensive hardware. However, user behaviors can change unpredictably, which renders it more challenging to develop systems that depend on them. In addition to dynamic behavior extraction, the proposed implicit authentication system differs from the existing systems in terms of energy efficiency for battery-powered mobile devices. Since implicit authentication systems rely on machine learning, the expensive training process needs to be outsourced to the remote server. However, mobile devices may not always have reliable network connections to send real-time data to the server for training. In addition, IA systems are still at their infancy and exhibit many limitations, one of which is how to determine the best retraining frequency when updating the user behavior model. Another limitation is how to gracefully degrade user privilege when authentication fails to identify legitimate users (i.e., false negatives) for a practical IA system.To address the retraining problem, we proposed an algorithm that utilizes Jensen-Shannon (JS)-dis(tance) to determine the optimal retraining frequency, which is discussed in Chapter 2. We overcame the limitation of traditional IA by proposing a W-layer, an overlay that provides a practical and energy-efficient solution for implicit authentication on mobile devices. The W-layer is discussed in Chapter 3 and 4. In Chapter 5, a novel privilege-control mechanism, BubbleMap (BMap), is introduced to provide fine-grained privileges to users based on their behavioral scores. In the same chapter, we describe reinforcement authentication (RA) to achieve a more reliable authentication

Periodontal Regeneration of Teeth with Radicular Developmental Groove after Intentional Replantation: Two Case Reports

Our case reports probe whether intentional replantation is a feasible and successful treatment for teeth with radicular developmental groove. Radicular developmental groove is an anatomical malformation that often leads to combined periodontal-endodontic lesion. Treatment of complex radicular groove presents a great challenge to the operator. Two cases of periodontal compromised teeth with this developmental anomaly were treated with intentional replantation and followed up for 2 years. The teeth were asymptomatic and functional. The periodontal probing depths decreased from original 10 mm to 2-3 mm. The receded gingival papillae associated with the teeth was regenerated two years after intentional replantation. With careful case selection and treatment planning, intentional replantation may be a predictable alternative treatment modality for the combined endodontic‐periodontal lesion accompanied with radicular developmental groove

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)